Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q33916030)
Watch
English
The ubiquitin-proteasome system as a molecular target in solid tumors: an update on bortezomib.
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMC publication ID
2886336
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20616904%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 February 2020
review article
1 reference
stated in
Europe PubMed Central
title
The ubiquitin-proteasome system as a molecular target in solid tumors: an update on bortezomib
(English)
1 reference
stated in
Europe PubMed Central
PMC publication ID
2886336
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20616904%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 February 2020
main subject
ubiquitin-proteasome system
0 references
author
Francesco Perri
series ordinal
2
1 reference
stated in
Europe PubMed Central
PMC publication ID
2886336
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20616904%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 February 2020
author name string
A Milano
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMC publication ID
2886336
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20616904%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 February 2020
F Caponigro
series ordinal
3
1 reference
stated in
Europe PubMed Central
PMC publication ID
2886336
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20616904%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 February 2020
language of work or name
English
0 references
publication date
18 February 2009
1 reference
stated in
Europe PubMed Central
PMC publication ID
2886336
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20616904%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 February 2020
published in
OncoTargets and Therapy
1 reference
stated in
Europe PubMed Central
PMC publication ID
2886336
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20616904%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 February 2020
volume
2
1 reference
stated in
Europe PubMed Central
PMC publication ID
2886336
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20616904%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 February 2020
page(s)
171-178
1 reference
stated in
Europe PubMed Central
PMC publication ID
2886336
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20616904%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 February 2020
copyright license
Creative Commons Attribution-NonCommercial 3.0 Unported
start time
1 June 2009
1 reference
stated in
April 2022 Public Data File from Crossref
copyright status
copyrighted
0 references
cites work
Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
5 July 2018
Bortezomib for the treatment of mantle cell lymphoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
5 July 2018
The proteasome: a worthwhile target for the treatment of solid tumours?
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
5 July 2018
A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
5 July 2018
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
5 July 2018
Can NF-kappaB be a target for novel and efficient anti-cancer agents?
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
5 July 2018
Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
5 July 2018
Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
5 July 2018
The proteasome and proteasome inhibitors in cancer therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
5 July 2018
Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
5 July 2018
A phase II study of bortezomib in the treatment of metastatic malignant melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
5 July 2018
A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
5 July 2018
Putting the rap on Akt.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
5 July 2018
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
5 July 2018
Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
5 July 2018
Back to the future with ubiquitin
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
5 July 2018
Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
5 July 2018
A phase 2 study of bortezomib in relapsed, refractory myeloma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
5 July 2018
The proteasome: structure, function, and role in the cell
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
5 July 2018
Proteasome inhibitors as therapeutic agents: current and future strategies.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
5 July 2018
NF-kappaB in cancer: from innocent bystander to major culprit
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
5 July 2018
The proteasome: a novel target for cancer chemotherapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
5 July 2018
The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
5 July 2018
26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
5 July 2018
Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
5 July 2018
The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
5 July 2018
Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
5 July 2018
Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
5 July 2018
The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
5 July 2018
TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
5 July 2018
Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
5 July 2018
An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
29 October 2018
Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
29 October 2018
The ubiquitin proteasome pathway from bench to bedside
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
29 October 2018
Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
29 October 2018
PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
29 October 2018
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
29 October 2018
A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
29 October 2018
Phase II trial of bortezomib for patients with advanced renal cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
29 October 2018
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
29 October 2018
Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
29 October 2018
The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
29 October 2018
Ethanol withdrawal induced CYP2E1 degradation in vivo, blocked by proteasomal inhibitor PS-341.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
29 October 2018
Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
29 October 2018
Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
29 October 2018
Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
29 October 2018
Proteolytic degradation of heme-modified hepatic cytochromes P450: A role for phosphorylation, ubiquitination, and the 26S proteasome?
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886336
retrieved
29 October 2018
Randomized Phase II Study of Bortezomib Alone and Bortezomib in Combination With Docetaxel in Previously Treated Advanced Non–Small-Cell Lung Cancer
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/20616904
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
The stabilization mechanism of mutant-type p53 by impaired ubiquitination: the loss of wild-type p53 function and the hsp90 association
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/20616904
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
The proteasome is involved in angiogenesis
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/20616904
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.2147/OTT.S4503
1 reference
stated in
Europe PubMed Central
PMC publication ID
2886336
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20616904%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 February 2020
PMC publication ID
2886336
1 reference
stated in
Europe PubMed Central
PMC publication ID
2886336
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20616904%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 February 2020
PubMed publication ID
20616904
1 reference
stated in
Europe PubMed Central
PMC publication ID
2886336
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20616904%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 February 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
